Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Willis Tower Watson in its divestment of Max Matthiessen
Mandate

Vinge advises Willis Tower Watson in its divestment of Max Matthiessen

May 25, 2020 Banking and Finance EU, Competition and Regulatory M&A Insurance Law Corporate Tax

Vinge advises Willis Tower Watson, global risk adviser, insurance and reinsurance broker, in its divestment of Max Matthiessen to Nordic Capital.

Max Matthiessen was founded 1889 and as active in insurance brokerage and financial advisory services for companies and individuals. The company has 440 employees at approximately 30 locations throughout Sweden with headquarter in Stockholm. In 2019, Max Matthiessen had a customer base of around 13,000 clients with revenues exceeding SEK 1.5 billion. Willis Tower Watson acquired Max Matthiessen from Altor 2014.

The acquisition is conditional upon customary regulatory approvals and conditions to closing.

Vinge’s team consisted of, amongst others, Peter Sundgren, Joacim Rydergård, Stina Bengtsson and Olivia Belding (M&A), Fabian Ekeblad and Paulina Malmberg (Regulatory Insurance), Albert Wållgren (Banking & Finance), Maria Schultzberg (Tax), Xandra Ståhlberg (Competition law) and Nathalie Hughes (VDR-assistant).

 

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

 Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026